Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.

Autor:	Muccini C; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.; Unit of Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milan, Italy., Canetti D; Unit of Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milan, Italy., Castagna A; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.; Unit of Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milan, Italy., Spagnuolo V; Unit of Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Hospital, Milan, Italy.
Jazyk:	angličtina
Zdroj:	Drug design, development and therapy [Drug Des Devel Ther] 2022 Jan 25; Vol. 16, pp. 297-304. Date of Electronic Publication: 2022 Jan 25 (Print Publication: 2022).
DOI:	10.2147/DDDT.S273660
Abstrakt:	Heavily-treatment-experienced people living with human immunodeficiency virus (HTE-PLWH) represent a population with limited therapeutic options and at high-risk of clinical progression, morbidity, and mortality. The development of new drugs and new drug classes for the treatment of HIV-1 infection in HTE-PLWH is critical to successfully suppress HIV-1 replication, restore the immune system, and improve quality of life. Fostemsavir is the first attachment inhibitor approved by Food and Drug Administration and European Medicines Agency for the treatment of HIV-1 infection. It is approved in combination with other antiretrovirals, for HTE-PLWH with multi-drug resistant HIV-1 after failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. In this review, we present and discuss the mechanism of action, the pharmacodynamic and pharmacokinetic properties, and the efficacy and safety of fostemsavir as an antiretroviral agent for the treatment of HIV-1 infection. Competing Interests: V.S. received speaking fees by Gilead Sciences, ViiV Healthcare, Merck Sharp and Dohme, Janssen-Cilag. A.C. received speaking fees by Gilead Sciences, ViiV Healthcare, Merck Sharp and Dohme, Janssen-Cilag, and Theratechnologies. The authors report no other conflicts of interest in this work. (© 2022 Muccini et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu